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A group of phorbol diesters has been identified as 
the active principles in tumor-promoting croton oil 
[I] among which 12-U-tetradecanoyl-phorbol-13- 
acetate was found to be the most abundant and one 
of the most active tumor promoters [2]. Tumor- 
promoting activity is classically tested by the ability 
to induce malignant epithelioma when applied 
repetitively to mouse skin pre-treated with a single 
subthreshold application of a carcinogen [3,4]. 
Phorbd esters elicit a variety of biological effects 
that have been observed in many different cell types, 
in vivo and in vitro. It is considered that TPA reversibly 
converts a normal phenotype to one that more 
closely resembles the transformed phenotype. Recent 
studies in cell culture systems have shown that TPA 
induces alterations which are currently associated with 
cell transformation, such as stimulation of glucose 
uptake [S], induction of plasminogen activator [6], 
decrease of surface LETS protein [7] or higher levels 
of saturation density 181. 
An impaired hormonal responsiveness of adenylate 
cyclase has also been associated with tr~sfo~ation 
[9,10] and the metastatic potential of melanoma cells 
has been positively correlated with the loss of ability to 
respond to hormonal stimulation [111. The adenylate 
cyclase system of epidermis after TPA applications to 
AbbrevWionr cyclic AMP, cyclic adenosine 3’,5’-monophos- 
phate, PBS, phosphate-buffered saline; TPA, 12-Gtetra- 
decanoyl-phorbol-13atate; MePDD, 4-O-methyl-phorbol- 
12-l fdidecanoate; PGE,, prostaglandin E,
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mouse skin has been examined 1121 and TPA was 
shown to decrease cyclic AMP accumula~on. It was 
suggested that TPA changed the adrenergic receptors 
of epidermal cells from @- to tu-adrenergic [ 121. 
This study investigated the effect of TPA on the 
cyclic AMP response of cultured rat embryo fibro- 
blasts after hormonal stimulation, We report that 
TPA induced a refractory state of a heterologous 
type, involving response to catecholamines and PGEr 
in these cells, In contrast, results failed to support 
evidence for a TPA-mediated linkage of adenylate 
cyclase to or-adrenergic receptor. 
2. Materials and methods 
PGEr was obtained from Sigma (St Louis) and 
used as solution in 95% ethanol. DLisoproterenol, 
Lepinephrine and Lphenylephrine were also 
purchased from Sigma and used as aqueous olutions 
in PBS. TPA and MePDD, kindly donated by 
Professor E. Hecker from Deutsches Krebsforschungs- 
zentrum (Heidelberg) were used as solutions in 
acetone. 
The experiments were with secondary cultures of 
rat embryo cells obtained from day 14 embryos 
according to [ 131. Cells were used 6 days after seed- 
ing, when they reached 2 X lo5 cells/ml and became 
confluent. After the addition of PGEr or adrenergic 
agonists to the culture medium, the incubation was 
continued at 37’C for 5,lO or 30 min in air con- 
taining 5% COs. At appropriate times, the medium 
was removed by aspiration and the cells were washed 
once with ice-cold PBS within seconds. Then 2 ml 
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cold 6% trichloroacetic acid was added to the culture 
dishes. The tissue extract was neutralized, concen- 
trated and assayed for cyclic AMP as in [ 141, whereas 
the acid-precipitable material dissolved in 0.6 N NaOH 
was used for protein determination by the Lowry 
method [ 1.51. In parallel experiments, cells were pre- 
incubated for 1,3 or 6 h in the presence of either 
TPA, MePDD or acetone before the cyclic AMP 
response to hormones was measured. 
3. Results 
Figure 1 depicts the accumulation of cyclic AMP 
in confluent rat embryo cells in response to PGEl 
or catecholamines in relation to time. PGEr was the 
most effective in eliciting cyclic AMP accumulation. 
The cyclic AMP levels rose very rapidly, reached a
value corresponding to5times the basal level in < 5 mm 
and returned to the control values by 30 min. Rat 
embryo fibroblasts were also responsive to Lepine- 
phrine and DLisoproterenol but to a much lesser 
extent. In contrast, cells pre-treated with TPA at 
100 ng/ml for 9 h were no longer responsive to PGEr 
and /3-adrenergic agonists, whereas the basal cyclic 
AMP levels were not significantly affected. 
Similarly, the effect of TPA on the response to 
phenylephrine was also tested in the rat embryo cell 
cultures. As shown table I, TPA-treated cells did not 
exhibit an enhanced accumulation of cyclic AMP in 
response to the a-agonist under conditions where the 
response to fl-adrenergic agonists was inhibited. 
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Fig.1. Cyclic AMP levels of rat embryo fibroblasts after 
various periods of exposure to PGE, , L-epmephrine or 
DL-isoproterenol. Hormones were added at 10 &M eithef to 
cells pretreated with TPA at 100 ng/mJ for 9 h (-g--) or to 
untreated cells (-a-). Unstimulated controls were run with 
PGE, or catecholamine solvents (-o-). 
The degree of refractoriness depended on dose 
and duration of the treatment with the tumor pro- 
moter. Figure 2 shows the relative ffects of both 
parameters on the cyclic AMP accumulation i  
response to PGEr . TPA-mediated inhibitory effect 
was detectable at as low as 1 &ml for a 9 h pretreat- 
ment, whereas at 100 ng/ml a 3 h pretreatment was 
sufficient for eliciting the loss of responsiveness to 
PGEr . 
MePDD was similarly tested. After a 9 h pretreat- 
ment, the TPA derivative, which is devoid of tumor- 
Table 1 
Effect of TPA on the accumulation of cyclic AMP foBowing exposure to 
phenylephrine in rat embryo fibroblasts 
Treatment Phenylephrine Cyclic AMP (pmol/mg protein) 
(NM) 
Omin Smin 10min 30 min 
Controls 1 44.8 * 1.6 39.2 f 3.2 42.8 i 1.1 31.1 f 1.8 
10 45.3 f 2.1 47.7 * 1.0 42.2 f 2.2 35.6 f 0.8 
Acetonepre- 1 43.7 i 0.7 43.3 * 1.3 40.6 f 1.9 39.9 f 2.3 
treated cells 10 39.7 i 3.2 40.8 f 1.7 39.9 f 2.8 42.1 f 1.5 
TPA-pretrea- 1 45.4 i 4.3 44.2 f 0.5 42.8 f 2.8 37.8 i 2.5 
ted cells 10 43.7 * 2.2 45.4 f 2.0 39.2 f 3.7 40.7 f 2.9 
Cells were preincubated for 9 h in presence of TPA at 100 ng/ml prior to exposure to 
the or-agonist. Results represent mean values of 4 determinations * SE 
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TIME AFTER EXPOSURE TO TPA (hr.) 
Fig.2. Cyclic AMPresponse to PGE, of rat embryo fibroblasts 
pretreated for various periods of time with graded doses of 
TPA: 1 r&ml (--o-_); 10 &ml (-A-); 100 ng/mf (-•-). 
The cyclic AMPlevels were measured 5 min after the addition 
of 10 PM PGE, . Control values represent he increase in the 
cyclic AMP content of untreated cells which were exposed 
for 5 min to 10 PM PGE,. 
promoting activity, was found to be > 103-fold less 
effective than TPA in inducing refractoriness toPGEr 
of rat embryo fibroblasts (fig.3). 
It should be stressed that acetone, the phorbol 
ester solvent, did not affect, at the concentrations 
used (< O.i%), either basal or stimulated levels of 
cyclic AMP. 
4. Discussion 
We report here that TPA causes the refractoriness 
of the adenylate cyclase system to &adrenergic agonists 
in cultured rat embryo fibroblasts. These results con- 
firm the decrease in the responsiveness to @-adrenergic 
agonists observed [ 121 following topical applications 
of TPA on mouse epidermis. However, no evidence 
was found to confirm the suggestion, [ 121, that TPA 
caused the change from fi- to cr-adrenergic receptors 
since phenylephrine did not elevate ~tracell~ar 
cyclic AMP of either untreated or treated cells. A 
PHORBOL ESTER CONCENTRATIVE (~g/ml) 
Fig.3. Responsiveness of rat embryo fibroblasts to PGE, 
following a 9 h pretreatment with either the tumor- 
promoting TPA (--A-) or the inactive derivative MePDD 
(-A-). The intraceklar cyclic AMP content was measured 
5 min after exposure to 10 PM PGE, . 
similar conclusion was drawn [lo] as a result of a 
study on mouse skin. 
This study also provides evidence for a hetero- 
Iogous type of refractoriness tohormones following 
TPA trea~ent since the tumor promoter also 
mediates at~edependent loss of responsiveness of 
rat embryo fibroblasts to PGEr. The TPA derivative 
MePDD, inactive as tumor promoter, was much less 
effective. 
Although it was reported [171 that TPA caused 
the induction of low-affinity cyclic nucleotide phos- 
phodiesterase activity in mouse epidermis, the 
possibility that an increased breakdown of cyclic 
AMP could account for the observed lack of respons- 
iveness eems unlikely. Recently it has been indeed 
reported that injections of isobutyl-methy~~t~me, 
a potent cyclic nucleotide pho~ho~esterase inhibitor, 
did not overcome the TPA-mediated suppression of
40 
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hormonal response in mouse skin [ 181. Similarly we levels of cyclic AMP are unaffected, the possibility 
failed to restore the normal response to hormones in that TPA may enhance the efflux of hormone- 
TPA-treated fibroblasts receiving 1mM aminophylline elevated intracellular cyclic AMP cannot be ruled out. 
(unpublished results). Further, the possibility has It may be worth stressing that the presented 
been raised that the induction of cyclic nucleotide characteristics of the TPA-induced refractoriness are 
phosphodiesterase observed in mouse skin was common to those of the agonist-induced loss of 
unrelated to the induction of the refractory state since responsiveness to hormones. Both processes did not 
it seems to a result of the various treatments, uch as abolish basal and fluoride-stimulated activities, did 
skin depilation and stripping, preceding the deter- not seem to involve cyclic nucleotide phosphodi- 
mination of cyclic AMP content of mouse skin. esterase and required a lag phase before being expressed 
Those treatments did not interfere significantly with thereby suggesting that TPA interferes with the 
the accumulation of cyclic AMP after fl-adrenergic mechanism by which cells did not loose their 
stimulation [181. responsiveness to their agonists. 
An alternative candidate for the site of TPA- 
mediated refractoriness would be the hormone-sen- 
sitive adenylate cyclase system. Acknowledgements 
Studies conducted in secondary cultures of rat 
embryo cells have shown that the tumor promoter 
stimulated cell proliferation and released confluent 
cells from quiescence [ 191. As cells progressed into 
the pre-replicative phase of the mitotic cycle, the basal 
levels of cyclic AMP and adenylate cyclase activity 
rose from 2-6 h after the TPA treatment and 
returned to control values by 9 h, at the onset of 
DNA synthesis. Levels of cyclic AMP content and 
adenylate cyclase activity were similar to those of 
serum-stimulated cells. Further, the fluoride stimula- 
tion of adenylate cyclase activity was found unchanged 
in TPA-treated cells [20]. As a consequence, it can be 
assumed that the induced refractory state to hormones 
is not due to a temporary inactivation of adenylate 
cyclase . 
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